Evidence map›Paper›PMID 34241570›Full record

ArticleAutophagy2022

Targeting autophagy in disease: established and new strategies.

Muhammed Kocak, Saba Ezazi Erdi, Guillem Jorba, Inés Maestro, Judith Farrés, Vladimir Kirkin, Ana Martinez, Ole Pless

Open access · bronzeAbstract read
In one paragraph

Article in Autophagy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
22.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 209 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Pharmaceutics · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Muhammed KocakCancer Research UK, Cancer Therapeutics Unit, the Institute of Cancer Research London, Sutton, UK.ORCID 0000-0002-7889-680X
Saba Ezazi ErdiFraunhofer ITMP ScreeningPort, Hamburg, Germany.ORCID 0000-0001-5628-7520
Guillem JorbaAnaxomics Biotech SL, Barcelona, Spain.ORCID 0000-0001-5209-5353
Inés MaestroCentro De Investigaciones Biologicas "Margarita Salas"-CSIC, Madrid, Spain.ORCID 0000-0002-5026-5803
Judith FarrésAnaxomics Biotech SL, Barcelona, Spain.
Vladimir KirkinCancer Research UK, Cancer Therapeutics Unit, the Institute of Cancer Research London, Sutton, UK.ORCID 0000-0002-8049-3663
Ana MartinezCentro De Investigaciones Biologicas "Margarita Salas"-CSIC, Madrid, Spain.ORCID 0000-0002-2707-8110
Ole PlessFraunhofer ITMP ScreeningPort, Hamburg, Germany.ORCID 0000-0002-1468-316X
Anaxomics (Spain) · ESFraunhofer Institute for Translational Medicine and Pharmacology · DEInstitute of Cancer Research · GBCentro de Investigaciones Biológicas Margarita Salas · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington,

Indexed as

COVID-19Neurodegenerative DiseasesAnimalsAutophagyClass III Phosphatidylinositol 3-KinasesSARS-CoV-2Class III Phosphatidylinositol 3-KinasesAutophagy activatorsautophagy inhibitorsautophagy modulatorsclinical trialsdrug discovery

Identifiers

PMID34241570
PMCPMC9037468
OpenAlexW3178393591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.